25 XP   0   0   10

Sinovac Biotech Ltd
Buy, Hold or Sell?

Let's analyse Sinovac Biotech Ltd together

PenkeI guess you are interested in Sinovac Biotech Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sinovac Biotech Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sinovac Biotech Ltd

I send you an email if I find something interesting about Sinovac Biotech Ltd.

Quick analysis of Sinovac Biotech Ltd (30 sec.)










What can you expect buying and holding a share of Sinovac Biotech Ltd? (30 sec.)

How much money do you get?

How much money do you get?
$9.22
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
$111.35
Expected worth in 1 year
$69.88
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$-32.25
Return On Investment
-498.4%

For what price can you sell your share?

Current Price per Share
$6.47
Expected price per share
$6.47 - $6.47
How sure are you?
50%

1. Valuation of Sinovac Biotech Ltd (5 min.)




Live pricePrice per Share (EOD)

$6.47

Intrinsic Value Per Share

$-41.08 - $299.86

Total Value Per Share

$70.26 - $411.20

2. Growth of Sinovac Biotech Ltd (5 min.)




Is Sinovac Biotech Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$12.7b$13.8b-$1.1b-9.2%

How much money is Sinovac Biotech Ltd making?

Current yearPrevious yearGrowGrow %
Making money$113.8m$8.4b-$8.3b-7,336.4%
Net Profit Margin7.6%43.7%--

How much money comes from the company's main activities?

3. Financial Health of Sinovac Biotech Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Sinovac Biotech Ltd? (5 min.)

Welcome investor! Sinovac Biotech Ltd's management wants to use your money to grow the business. In return you get a share of Sinovac Biotech Ltd.

What can you expect buying and holding a share of Sinovac Biotech Ltd?

First you should know what it really means to hold a share of Sinovac Biotech Ltd. And how you can make/lose money.

Speculation

The Price per Share of Sinovac Biotech Ltd is $6.47. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sinovac Biotech Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sinovac Biotech Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $111.35. Based on the TTM, the Book Value Change Per Share is $-10.37 per quarter. Based on the YOY, the Book Value Change Per Share is $111.86 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $2.31 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sinovac Biotech Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps1.0015.4%1.0015.4%74.271,147.9%15.35237.3%7.71119.1%
Usd Book Value Change Per Share-10.37-160.2%-10.37-160.2%111.861,728.9%22.01340.2%11.00170.1%
Usd Dividend Per Share2.3135.6%2.3135.6%16.45254.3%3.7558.0%1.8829.0%
Usd Total Gains Per Share-8.06-124.6%-8.06-124.6%128.311,983.2%25.76398.1%12.88199.1%
Usd Price Per Share6.47-6.47-6.47-6.56-6.37-
Price to Earnings Ratio6.49-6.49-0.09-12.62--155.18-
Price-to-Total Gains Ratio-0.80--0.80-0.05-5.67--59.56-
Price to Book Ratio0.06-0.06-0.05-1.03-2.78-
Price-to-Total Gains Ratio-0.80--0.80-0.05-5.67--59.56-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.47
Number of shares154
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share2.313.75
Usd Book Value Change Per Share-10.3722.01
Usd Total Gains Per Share-8.0625.76
Gains per Quarter (154 shares)-1,241.573,967.02
Gains per Year (154 shares)-4,966.2915,868.07
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11420-6386-497623111355715858
22840-12772-994246222711431726
34260-19159-1490869334067147594
45680-25545-1987492455422863462
57099-31931-24840115566778579330
68519-38317-29806138678134295198
79939-44703-347721617894898111066
811359-51089-3973818489108455126934
912779-57476-4470420800122012142802
1014199-63862-4967023112135569158670

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%7.03.00.070.0%10.014.00.041.7%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%5.04.01.050.0%16.07.01.066.7%
Dividend per Share1.00.00.0100.0%2.00.01.066.7%2.00.03.040.0%4.00.06.040.0%10.00.014.041.7%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%5.04.01.050.0%16.07.01.066.7%

Fundamentals of Sinovac Biotech Ltd

About Sinovac Biotech Ltd

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-04-20 14:49:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sinovac Biotech Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sinovac Biotech Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Sinovac Biotech Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 7.6% means that $0.08 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sinovac Biotech Ltd:

  • The MRQ is 7.6%. The company is making a profit. +1
  • The TTM is 7.6%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ7.6%TTM7.6%0.0%
TTM7.6%YOY43.7%-36.1%
TTM7.6%5Y20.1%-12.5%
5Y20.1%10Y10.5%+9.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.6%-199.6%+207.2%
TTM7.6%-213.0%+220.6%
YOY43.7%-279.3%+323.0%
5Y20.1%-438.4%+458.5%
10Y10.5%-605.5%+616.0%
1.1.2. Return on Assets

Shows how efficient Sinovac Biotech Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sinovac Biotech Ltd to the Biotechnology industry mean.
  • 0.8% Return on Assets means that Sinovac Biotech Ltd generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sinovac Biotech Ltd:

  • The MRQ is 0.8%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.8%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.8%TTM0.8%0.0%
TTM0.8%YOY50.6%-49.8%
TTM0.8%5Y14.6%-13.8%
5Y14.6%10Y7.4%+7.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8%-13.5%+14.3%
TTM0.8%-12.9%+13.7%
YOY50.6%-11.8%+62.4%
5Y14.6%-14.1%+28.7%
10Y7.4%-16.0%+23.4%
1.1.3. Return on Equity

Shows how efficient Sinovac Biotech Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sinovac Biotech Ltd to the Biotechnology industry mean.
  • 1.3% Return on Equity means Sinovac Biotech Ltd generated $0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sinovac Biotech Ltd:

  • The MRQ is 1.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.3%TTM1.3%0.0%
TTM1.3%YOY90.8%-89.5%
TTM1.3%5Y26.1%-24.9%
5Y26.1%10Y13.3%+12.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3%-16.9%+18.2%
TTM1.3%-16.1%+17.4%
YOY90.8%-15.1%+105.9%
5Y26.1%-19.9%+46.0%
10Y13.3%-20.9%+34.2%

1.2. Operating Efficiency of Sinovac Biotech Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sinovac Biotech Ltd is operating .

  • Measures how much profit Sinovac Biotech Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sinovac Biotech Ltd to the Biotechnology industry mean.
  • An Operating Margin of 2.1% means the company generated $0.02  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sinovac Biotech Ltd:

  • The MRQ is 2.1%. The company is operating less efficient.
  • The TTM is 2.1%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ2.1%TTM2.1%0.0%
TTM2.1%YOY90.7%-88.5%
TTM2.1%5Y37.1%-35.0%
5Y37.1%10Y22.7%+14.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1%-295.1%+297.2%
TTM2.1%-225.8%+227.9%
YOY90.7%-288.4%+379.1%
5Y37.1%-477.4%+514.5%
10Y22.7%-625.6%+648.3%
1.2.2. Operating Ratio

Measures how efficient Sinovac Biotech Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.31 means that the operating costs are $1.31 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Sinovac Biotech Ltd:

  • The MRQ is 1.309. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.309. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.309TTM1.3090.000
TTM1.309YOY0.094+1.215
TTM1.3095Y0.701+0.608
5Y0.70110Y0.825-0.124
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3093.090-1.781
TTM1.3093.264-1.955
YOY0.0943.783-3.689
5Y0.7015.679-4.978
10Y0.8257.894-7.069

1.3. Liquidity of Sinovac Biotech Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sinovac Biotech Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 11.11 means the company has $11.11 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Sinovac Biotech Ltd:

  • The MRQ is 11.108. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.108. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ11.108TTM11.1080.000
TTM11.108YOY6.182+4.927
TTM11.1085Y5.695+5.413
5Y5.69510Y3.982+1.713
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.1083.914+7.194
TTM11.1084.220+6.888
YOY6.1825.388+0.794
5Y5.6956.045-0.350
10Y3.9826.406-2.424
1.3.2. Quick Ratio

Measures if Sinovac Biotech Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sinovac Biotech Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 17.37 means the company can pay off $17.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sinovac Biotech Ltd:

  • The MRQ is 17.365. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.365. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ17.365TTM17.3650.000
TTM17.365YOY6.703+10.662
TTM17.3655Y7.056+10.310
5Y7.05610Y4.494+2.562
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.3653.572+13.793
TTM17.3653.998+13.367
YOY6.7035.390+1.313
5Y7.0565.969+1.087
10Y4.4946.287-1.793

1.4. Solvency of Sinovac Biotech Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sinovac Biotech Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sinovac Biotech Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Sinovac Biotech Ltd assets are financed with 9.9% credit (debt) and the remaining percentage (100% - 9.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sinovac Biotech Ltd:

  • The MRQ is 0.099. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.099. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.099TTM0.0990.000
TTM0.099YOY0.171-0.072
TTM0.0995Y0.223-0.123
5Y0.22310Y0.302-0.080
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0990.336-0.237
TTM0.0990.334-0.235
YOY0.1710.269-0.098
5Y0.2230.366-0.143
10Y0.3020.390-0.088
1.4.2. Debt to Equity Ratio

Measures if Sinovac Biotech Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sinovac Biotech Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 15.7% means that company has $0.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sinovac Biotech Ltd:

  • The MRQ is 0.157. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.157. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.157TTM0.1570.000
TTM0.157YOY0.308-0.151
TTM0.1575Y0.432-0.275
5Y0.43210Y0.564-0.132
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1570.382-0.225
TTM0.1570.396-0.239
YOY0.3080.335-0.027
5Y0.4320.434-0.002
10Y0.5640.465+0.099

2. Market Valuation of Sinovac Biotech Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Sinovac Biotech Ltd generates.

  • Above 15 is considered overpriced but always compare Sinovac Biotech Ltd to the Biotechnology industry mean.
  • A PE ratio of 6.49 means the investor is paying $6.49 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sinovac Biotech Ltd:

  • The EOD is 6.487. Based on the earnings, the company is cheap. +2
  • The MRQ is 6.487. Based on the earnings, the company is cheap. +2
  • The TTM is 6.487. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD6.487MRQ6.4870.000
MRQ6.487TTM6.4870.000
TTM6.487YOY0.087+6.400
TTM6.4875Y12.618-6.130
5Y12.61810Y-155.177+167.795
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.487-2.259+8.746
MRQ6.487-2.569+9.056
TTM6.487-2.664+9.151
YOY0.087-4.120+4.207
5Y12.618-6.258+18.876
10Y-155.177-6.171-149.006
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sinovac Biotech Ltd:

  • The EOD is -0.629. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.629. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.629. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.629MRQ-0.6290.000
MRQ-0.629TTM-0.6290.000
TTM-0.629YOY0.050-0.680
TTM-0.6295Y64.443-65.072
5Y64.44310Y109.695-45.252
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.629-2.924+2.295
MRQ-0.629-3.246+2.617
TTM-0.629-3.488+2.859
YOY0.050-5.620+5.670
5Y64.443-8.315+72.758
10Y109.695-8.826+118.521
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sinovac Biotech Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.06 means the investor is paying $0.06 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Sinovac Biotech Ltd:

  • The EOD is 0.058. Based on the equity, the company is cheap. +2
  • The MRQ is 0.058. Based on the equity, the company is cheap. +2
  • The TTM is 0.058. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.058MRQ0.0580.000
MRQ0.058TTM0.0580.000
TTM0.058YOY0.053+0.005
TTM0.0585Y1.029-0.971
5Y1.02910Y2.775-1.746
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0581.851-1.793
MRQ0.0582.090-2.032
TTM0.0582.095-2.037
YOY0.0532.844-2.791
5Y1.0293.466-2.437
10Y2.7753.815-1.040
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Sinovac Biotech Ltd.

3.1. Institutions holding Sinovac Biotech Ltd

Institutions are holding 32.025% of the shares of Sinovac Biotech Ltd.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Orbimed Advisors, LLC2.73236.7902271873500
2023-12-31Neumann Advisory Hong Kong Ltd0.31720.779331558600
2023-12-31California Public Employees Retrmnt Sys0.069106873200
2023-09-30Spark Investment Management LLC0.029202910000
2023-09-30Northern Trust Corp0.013901378700
2023-12-31Navellier & Associates Inc0.0137013641-1008-6.881
2023-09-30Advisor Group Holdings, Inc.0.00140136200
2023-09-30Hartland & Co0.00101000500100
2023-12-31Financial Gravity Wealth, Inc.0.0010.035298800
2023-09-30Royal Bank of Canada0.0005053300
2023-09-30Bank of America Corp0.0004042600
2023-09-30Tower Research Capital LLC0.0004042400
2023-09-30U.S. Bancorp0.0001012700
2023-12-31Horizon Investments0.000105200
2023-12-31Genworth Financial Wealth Mgmt Inc0013-1-7.1429
2023-12-31Transamerica Financial Advisors Inc00.0001220
2023-12-31Vivo Capital, LLC000-5900000-100
2023-12-31State Street Corporation000-160875-100
2023-12-31Susquehanna International Group, LLP000-16430-100
2023-09-30Skandinaviska Enskilda Banken AB000-40000-100
Total 3.18037.60483164508-6117812-193.3%

3.2. Funds holding Sinovac Biotech Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Nasdaq Composite Index0.02790.00122771700
2023-12-31NT Quality SCC US Fund - L0.0070700000
2024-02-29AST JP Morgan Tactical Preservation0.0030.0004300000
2023-09-30Blackstone Alternative Multi-Strategy I0.00040.0001400200100
2024-03-31Aptus Impact Series Moderate00200
Total 0.03830.001738119+200+0.5%

3.3. Insider Transactions

Insiders are holding 51.421% of the shares of Sinovac Biotech Ltd.

DateOwnerTypeAmountPricePost Transaction AmountLink
2017-04-20Scott LangilleBUY1000000.27 
2017-04-19Scott LangilleBUY500000.27 
2017-04-18Scott LangilleBUY250000.26 
2017-04-17James Todd ParsonsSELL2720.25 
2017-04-17Scott LangilleBUY245000.26 
2017-04-13James Todd ParsonsSELL1665000.25 
2017-04-11James Todd ParsonsSELL335000.25 
2015-12-30Jeffrey BachaSELL100000.3 
2015-12-29Jeffrey BachaSELL215000.3 

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Sinovac Biotech Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---10.367-10.3670%111.858-109%22.008-147%11.004-194%
Book Value Per Share--111.346111.3460%121.713-9%49.813+124%25.592+335%
Current Ratio--11.10811.1080%6.182+80%5.695+95%3.982+179%
Debt To Asset Ratio--0.0990.0990%0.171-42%0.223-55%0.302-67%
Debt To Equity Ratio--0.1570.1570%0.308-49%0.432-64%0.564-72%
Dividend Per Share--2.3052.3050%16.454-86%3.752-39%1.877+23%
Eps--0.9970.9970%74.272-99%15.354-94%7.707-87%
Free Cash Flow Per Share---10.284-10.2840%128.349-108%24.288-142%12.067-185%
Free Cash Flow To Equity Per Share---12.398-12.3980%111.712-111%21.713-157%10.831-214%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.037-4%
Intrinsic Value_10Y_max--299.857--------
Intrinsic Value_10Y_min---41.081--------
Intrinsic Value_1Y_max--38.243--------
Intrinsic Value_1Y_min--8.069--------
Intrinsic Value_3Y_max--108.660--------
Intrinsic Value_3Y_min--13.833--------
Intrinsic Value_5Y_max--171.547--------
Intrinsic Value_5Y_min--8.144--------
Market Cap642436734.880-15%738697899.540738697899.5400%737618710.010+0%722104862.436+2%667376593.058+11%
Net Profit Margin--0.0760.0760%0.437-83%0.201-62%0.105-27%
Operating Margin--0.0210.0210%0.907-98%0.371-94%0.227-91%
Operating Ratio--1.3091.3090%0.094+1293%0.701+87%0.825+59%
Pb Ratio0.0580%0.0580.0580%0.053+9%1.029-94%2.775-98%
Pe Ratio6.4870%6.4876.4870%0.087+7347%12.618-49%-155.177+2492%
Price Per Share6.4700%6.4706.4700%6.4700%6.564-1%6.367+2%
Price To Free Cash Flow Ratio-0.6290%-0.629-0.6290%0.050-1348%64.443-101%109.695-101%
Price To Total Gains Ratio-0.8030%-0.803-0.8030%0.050-1692%5.673-114%-59.557+7321%
Quick Ratio--17.36517.3650%6.703+159%7.056+146%4.494+286%
Return On Assets--0.0080.0080%0.506-98%0.146-94%0.074-89%
Return On Equity--0.0130.0130%0.908-99%0.261-95%0.133-90%
Total Gains Per Share---8.062-8.0620%128.312-106%25.760-131%12.881-163%
Usd Book Value--12712661000.00012712661000.0000%13876009000.000-8%5670583600.000+124%2903412000.000+338%
Usd Book Value Change Per Share---10.367-10.3670%111.858-109%22.008-147%11.004-194%
Usd Book Value Per Share--111.346111.3460%121.713-9%49.813+124%25.592+335%
Usd Dividend Per Share--2.3052.3050%16.454-86%3.752-39%1.877+23%
Usd Eps--0.9970.9970%74.272-99%15.354-94%7.707-87%
Usd Free Cash Flow---1174113000.000-1174113000.0000%14632564000.000-108%2768177200.000-142%1376453200.000-185%
Usd Free Cash Flow Per Share---10.284-10.2840%128.349-108%24.288-142%12.067-185%
Usd Free Cash Flow To Equity Per Share---12.398-12.3980%111.712-111%21.713-157%10.831-214%
Usd Market Cap642436734.880-15%738697899.540738697899.5400%737618710.010+0%722104862.436+2%667376593.058+11%
Usd Price Per Share6.4700%6.4706.4700%6.4700%6.564-1%6.367+2%
Usd Profit--113866000.000113866000.0000%8467480000.000-99%1751685200.000-93%876174500.000-87%
Usd Revenue--1492761000.0001492761000.0000%19374904000.000-92%4370798400.000-66%2220097400.000-33%
Usd Total Gains Per Share---8.062-8.0620%128.312-106%25.760-131%12.881-163%
 EOD+0 -2MRQTTM+0 -0YOY+7 -265Y+13 -2210Y+15 -21

4.2. Fundamental Score

Let's check the fundamental score of Sinovac Biotech Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-156.487
Price to Book Ratio (EOD)Between0-10.058
Net Profit Margin (MRQ)Greater than00.076
Operating Margin (MRQ)Greater than00.021
Quick Ratio (MRQ)Greater than117.365
Current Ratio (MRQ)Greater than111.108
Debt to Asset Ratio (MRQ)Less than10.099
Debt to Equity Ratio (MRQ)Less than10.157
Return on Equity (MRQ)Greater than0.150.013
Return on Assets (MRQ)Greater than0.050.008
Total8/10 (80.0%)

4.3. Technical Score

Let's check the technical score of Sinovac Biotech Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 506.470
Ma 50Greater thanMa 1006.470
Ma 100Greater thanMa 2006.470
OpenGreater thanClose6.470
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Operating Income  45,31623,24668,562147,082215,64417,337,61317,553,257-18,019,324-466,067
Tax Provision  10,472-4,8675,60525,83331,4383,072,6923,104,130-3,167,023-62,893
Income Tax Expense  10,472-4,8675,60525,83331,4383,072,6923,104,130-3,167,023-62,893



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets14,114,568
Total Liabilities1,401,907
Total Stockholder Equity8,921,421
 As reported
Total Liabilities 1,401,907
Total Stockholder Equity+ 8,921,421
Total Assets = 14,114,568

Assets

Total Assets14,114,568
Total Current Assets12,126,396
Long-term Assets1,988,172
Total Current Assets
Cash And Cash Equivalents 4,278,124
Short-term Investments 7,034,569
Net Receivables 609,489
Inventory 180,719
Other Current Assets 23,495
Total Current Assets  (as reported)12,126,396
Total Current Assets  (calculated)12,126,396
+/-0
Long-term Assets
Property Plant Equipment 1,173,279
Long Term Investments 661,440
Intangible Assets 79,514
Long-term Assets Other 2,821
Long-term Assets  (as reported)1,988,172
Long-term Assets  (calculated)1,917,054
+/- 71,118

Liabilities & Shareholders' Equity

Total Current Liabilities1,091,635
Long-term Liabilities310,272
Total Stockholder Equity8,921,421
Total Current Liabilities
Short-term Debt 10,644
Short Long Term Debt 4,651
Accounts payable 19,825
Other Current Liabilities 1,028,091
Total Current Liabilities  (as reported)1,091,635
Total Current Liabilities  (calculated)1,063,211
+/- 28,424
Long-term Liabilities
Long term Debt 11,513
Capital Lease Obligations 58,509
Long-term Liabilities Other 240
Long-term Liabilities  (as reported)310,272
Long-term Liabilities  (calculated)70,262
+/- 240,010
Total Stockholder Equity
Common Stock100
Retained Earnings 7,225,987
Accumulated Other Comprehensive Income 1,154,737
Other Stockholders Equity 540,582
Total Stockholder Equity (as reported)8,921,421
Total Stockholder Equity (calculated)8,921,406
+/- 15
Other
Capital Stock115
Cash and Short Term Investments 11,312,693
Common Stock Shares Outstanding 114,173
Current Deferred Revenue33,075
Liabilities and Stockholders Equity 14,114,568
Net Debt -4,203,451
Net Invested Capital 8,937,570
Net Working Capital 11,034,761
Property Plant and Equipment Gross 1,052,367
Short Long Term Debt Total 74,673



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-31
> Total Assets 
34
34
269
222
236
14,898
22,420
23,367
31,299
57,448
83,203
145,477
214,358
215,908
208,763
240,693
238,530
202,927
211,355
211,355
369,780
452,299
1,901,326
16,748,174
14,114,568
14,114,56816,748,1741,901,326452,299369,780211,355211,355202,927238,530240,693208,763215,908214,358145,47783,20357,44831,29923,36722,42014,8982362222693434
   > Total Current Assets 
34
0
166
169
166
3,952
8,471
8,471
16,274
39,183
62,281
119,312
147,294
132,039
126,283
157,250
154,803
128,494
134,239
130,747
284,175
349,607
1,560,293
14,915,109
12,126,396
12,126,39614,915,1091,560,293349,607284,175130,747134,239128,494154,803157,250126,283132,039147,294119,31262,28139,18316,2748,4718,4713,952166169166034
       Cash And Cash Equivalents 
34
0
33
131
68
1,420
2,605
2,605
7,354
17,071
32,894
74,953
101,585
104,287
91,241
107,242
91,293
63,834
62,434
62,434
158,170
152,718
1,041,008
11,608,855
4,278,124
4,278,12411,608,8551,041,008152,718158,17062,43462,43463,83491,293107,24291,241104,287101,58574,95332,89417,0717,3542,6052,6051,4206813133034
       Short-term Investments 
0
0
0
0
0
0
391
149
24
1
0
7,313
1,512
0
0
0
1,500
0
0
0
18,908
50,274
135,248
1,806,449
7,034,569
7,034,5691,806,449135,24850,27418,9080001,5000001,5127,3130124149391000000
       Net Receivables 
0
0
10
10
16
1,471
3,353
3,353
5,454
16,984
19,487
25,541
25,768
17,834
23,440
31,927
40,719
39,021
49,832
49,832
77,463
113,736
253,487
952,402
609,489
609,489952,402253,487113,73677,46349,83249,83239,02140,71931,92723,44017,83425,76825,54119,48716,9845,4543,3533,3531,47116101000
       Other Current Assets 
0
0
123
3
82
14
1,195
1,195
2,190
1,381
348
1,906
3,569
1,805
1,072
3,752
4,079
1,797
7,871
4,379
4,543
5,033
24,737
171,892
23,495
23,495171,89224,7375,0334,5434,3797,8711,7974,0793,7521,0721,8053,5691,9063481,3812,1901,1951,1951482312300
   > Long-term Assets 
0
0
104
53
70
10,945
13,950
14,896
15,025
18,265
20,923
26,165
67,064
83,869
82,480
83,443
83,727
74,433
77,116
80,608
85,605
102,692
341,033
1,833,065
1,988,172
1,988,1721,833,065341,033102,69285,60580,60877,11674,43383,72783,44382,48083,86967,06426,16520,92318,26515,02514,89613,95010,945705310400
       Property Plant Equipment 
0
0
27
41
18
7,460
10,042
10,042
12,456
15,879
19,262
22,307
64,036
76,457
69,654
68,671
67,620
64,241
67,846
67,846
71,390
83,336
304,396
1,083,964
1,173,279
1,173,2791,083,964304,39683,33671,39067,84667,84664,24167,62068,67169,65476,45764,03622,30719,26215,87912,45610,04210,0427,46018412700
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
655,835
661,440
661,440655,83500000000000000000000000
       Intangible Assets 
0
0
0
0
2,300
2,538
1,230
2,344
1,917
1,394
1,090
695
1,348
1,336
12,062
11,720
10,613
9,574
8,697
8,697
8,304
7,965
9,721
41,210
79,514
79,51441,2109,7217,9658,3048,6978,6979,57410,61311,72012,0621,3361,3486951,0901,3941,9172,3441,2302,5382,3000000
       Other Assets 
0
0
76
52
56
947
2,510
652
589
992
570
3,163
1,680
6,905
1,247
3,760
4,553
10,520
13,726
18,901
14,685
21,746
55,355
0
0
0055,35521,74614,68518,90113,72610,5204,5533,7601,2476,9051,6803,1635709925896522,51094756527600
> Total Liabilities 
5
0
952
590
137
4,010
6,858
6,858
11,508
24,546
26,304
61,010
66,601
70,611
79,328
97,054
96,804
66,422
81,689
81,689
77,852
100,104
781,201
2,872,165
1,401,907
1,401,9072,872,165781,201100,10477,85281,68981,68966,42296,80497,05479,32870,61166,60161,01026,30424,54611,5086,8586,8584,01013759095205
   > Total Current Liabilities 
5
0
774
95
137
3,407
6,656
6,656
8,844
20,445
21,279
51,013
45,758
39,531
30,155
49,157
79,834
58,138
66,264
66,264
58,205
87,199
679,610
2,412,846
1,091,635
1,091,6352,412,846679,61087,19958,20566,26466,26458,13879,83449,15730,15539,53145,75851,01321,27920,4458,8446,6566,6563,4071379577405
       Short-term Debt 
0
0
2
2
3
752
2,605
2,605
2,418
6,836
8,024
17,698
10,436
4,713
3,329
19,541
49,970
24,245
33,583
33,583
3,321
13,077
42,613
15,066
10,644
10,64415,06642,61313,0773,32133,58333,58324,24549,97019,5413,3294,71310,43617,6988,0246,8362,4182,6052,60575232200
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37,740
51,687
32,241
4,331
33,583
18,152
3,321
12,541
39,096
4,681
4,651
4,6514,68139,09612,5413,32118,15233,5834,33132,24151,68737,74000000000000000
       Accounts payable 
0
0
42
37
63
1,484
336
2,519
697
776
1,371
3,791
2,273
2,945
2,170
6,063
3,033
1,715
1,834
1,834
5,530
5,783
30,543
58,590
19,825
19,82558,59030,5435,7835,5301,8341,8341,7153,0336,0632,1702,9452,2733,7911,3717766972,5193361,48463374200
       Other Current Liabilities 
0
0
729
56
71
1,170
3,715
1,532
5,729
12,833
11,884
45,336
43,563
61,447
45,694
22,220
21,305
22,832
21,915
52,608
44,461
60,139
227,290
2,246,690
1,028,091
1,028,0912,246,690227,29060,13944,46152,60821,91522,83221,30522,22045,69461,44743,56345,33611,88412,8335,7291,5323,7151,170715672900
   > Long-term Liabilities 
0
0
179
495
65
604
202
202
2,664
4,102
5,025
9,997
20,843
31,080
49,173
47,897
16,970
8,284
15,425
15,425
19,647
12,905
101,591
459,319
310,272
310,272459,319101,59112,90519,64715,42515,4258,28416,97047,89749,17331,08020,8439,9975,0254,1022,6642022026046549517900
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,803
756
9,448
14,849
3,890
1,436
0
0
0
0001,4363,89014,8499,4487561,8030000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
2,734
2,837
9,998
10,786
12,648
14,762
15,751
15,167
7,528
5,977
7,617
9,052
5,711
7,818
0
0
007,8185,7119,0527,6175,9777,52815,16715,75114,76212,64810,7869,9982,8372,734000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,751
14,685
0
0
0
0
0
0
0
0
0000000014,68515,751000000000000000
> Total Stockholder Equity
29
0
-683
-368
99
6,150
12,437
12,933
18,023
30,004
49,714
70,658
126,440
129,921
117,724
128,684
126,564
121,653
115,767
115,767
253,433
294,019
746,472
9,327,435
8,921,421
8,921,4219,327,435746,472294,019253,433115,767115,767121,653126,564128,684117,724129,921126,44070,65849,71430,00418,02312,93312,4376,15099-368-683029
   Common Stock
9
0
8
9
17
27
36
36
39
40
43
43
54
55
55
56
56
57
57
57
71
99
99
100
100
100100999971575757565655555443434039363627179809
   Retained Earnings 
-6
0
-888
-404
-1,063
-708
-6,155
-5,659
-11,551
-7,111
-1,652
13,993
3,876
2,696
-12,156
-4,714
-6,384
-9,980
-11,914
-11,914
23,820
56,731
144,241
7,141,819
7,225,987
7,225,9877,141,819144,24156,73123,820-11,914-11,914-9,980-6,384-4,714-12,1562,6963,87613,993-1,652-7,111-11,551-5,659-6,155-708-1,063-404-8880-6
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
108,243
109,944
112,668
115,339
204,998
207,962
0
0
0
000207,962204,998115,339112,668109,944108,2430000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
27
0
198
27
1,145
5,798
18,152
18,152
27,241
32,110
47,179
42,534
104,152
105,383
106,246
107,393
108,243
109,944
112,668
112,668
204,998
207,962
531,815
540,582
540,582
540,582540,582531,815207,962204,998112,668112,668109,944108,243107,393106,246105,383104,15242,53447,17932,11027,24118,15218,1525,7981,14527198027



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue1,492,761
Cost of Revenue-684,456
Gross Profit808,305808,305
 
Operating Income (+$)
Gross Profit808,305
Operating Expense-1,269,159
Operating Income-466,067-460,854
 
Operating Expense (+$)
Research Development442,108
Selling General Administrative823,543
Selling And Marketing Expenses0
Operating Expense1,269,1591,265,651
 
Net Interest Income (+$)
Interest Income190,818
Interest Expense-1,264
Other Finance Cost-0
Net Interest Income189,554
 
Pretax Income (+$)
Operating Income-466,067
Net Interest Income189,554
Other Non-Operating Income Expenses0
Income Before Tax (EBT)25,238-762,605
EBIT - interestExpense = 30,451
50,973
115,130
Interest Expense1,264
Earnings Before Interest and Taxes (EBIT)31,71526,502
Earnings Before Interest and Taxes (EBITDA)188,312
 
After tax Income (+$)
Income Before Tax25,238
Tax Provision--62,893
Net Income From Continuing Ops88,13188,131
Net Income113,866
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,953,615
Total Other Income/Expenses Net296,538-189,554
 

Technical Analysis of Sinovac Biotech Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sinovac Biotech Ltd. The general trend of Sinovac Biotech Ltd is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sinovac Biotech Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sinovac Biotech Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 6.47 < 6.47 < 6.47.

The bearish price targets are: 6.47 > 6.47 > 6.47.

Tweet this
Sinovac Biotech Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sinovac Biotech Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sinovac Biotech Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sinovac Biotech Ltd. The current macd is 0.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sinovac Biotech Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Sinovac Biotech Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Sinovac Biotech Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Sinovac Biotech Ltd Daily Moving Average Convergence/Divergence (MACD) ChartSinovac Biotech Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sinovac Biotech Ltd. The current adx is 0.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is 0/(-7 +7).

  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Sinovac Biotech Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sinovac Biotech Ltd. The current sar is 6.47.

Sinovac Biotech Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sinovac Biotech Ltd. The current rsi is 0. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Sinovac Biotech Ltd Daily Relative Strength Index (RSI) ChartSinovac Biotech Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sinovac Biotech Ltd. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sinovac Biotech Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Sinovac Biotech Ltd Daily Stochastic Oscillator ChartSinovac Biotech Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sinovac Biotech Ltd. The current cci is -66.66666667.

Sinovac Biotech Ltd Daily Commodity Channel Index (CCI) ChartSinovac Biotech Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sinovac Biotech Ltd. The current cmo is 0.

Sinovac Biotech Ltd Daily Chande Momentum Oscillator (CMO) ChartSinovac Biotech Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sinovac Biotech Ltd. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Sinovac Biotech Ltd Daily Williams %R ChartSinovac Biotech Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sinovac Biotech Ltd.

Sinovac Biotech Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sinovac Biotech Ltd. The current atr is 0.

Sinovac Biotech Ltd Daily Average True Range (ATR) ChartSinovac Biotech Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sinovac Biotech Ltd. The current obv is 0.

Sinovac Biotech Ltd Daily On-Balance Volume (OBV) ChartSinovac Biotech Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sinovac Biotech Ltd. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Sinovac Biotech Ltd Daily Money Flow Index (MFI) ChartSinovac Biotech Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sinovac Biotech Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal

6.3. Candlestick Patterns

Sinovac Biotech Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sinovac Biotech Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 506.470
Ma 50Greater thanMa 1006.470
Ma 100Greater thanMa 2006.470
OpenGreater thanClose6.470
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sinovac Biotech Ltd with someone you think should read this too:
  • Are you bullish or bearish on Sinovac Biotech Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sinovac Biotech Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sinovac Biotech Ltd

I send you an email if I find something interesting about Sinovac Biotech Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Sinovac Biotech Ltd.

Receive notifications about Sinovac Biotech Ltd in your mailbox!